Intuitive Surgical Confronts a New Rival Just as Its Growth Story Loses Momentum
Published on 07/23/2026 at 18:13 | Redaktion boerse-global.de
The robotic surgery pioneer that has dominated soft-tissue procedures for years is suddenly facing pressure from two directions at once. Intuitive Surgical’s shares have tumbled to within a whisker of their 52-week low, closing at €298.65, after the company absorbed a double blow: the U.S. Food and Drug Administration cleared Johnson & Johnson’s Ottava surgical robot for a wide range of abdominal operations, and the company’s own cautious full-year guidance disappointed investors who had hoped for an upgrade.
The FDA’s decision, announced on July 22, marks the culmination of nearly six years of development by J&J. Ottava received approval for procedures including Roux-en-Y gastric bypass, gastrectomies, cholecystectomies, splenectomies, sleeve gastrectomies, appendectomies, small bowel resections, and hiatal hernia repairs. J&J plans an initial commercial rollout with select U.S. hospital customers, aiming to build early momentum before expanding into additional indications and geographies.
It is the second major regulatory green light for a competing robotic surgery platform within a year. Medtronic’s Hugo system secured FDA clearance for urological procedures in late 2025, meaning Intuitive now faces credible challengers on multiple fronts simultaneously.
A Stock Already Under Siege
The market reaction to the J&J news was swift, but it landed on a stock that was already in distress. Intuitive shares had fallen roughly 35 percent from the start of the year before the FDA announcement, and the past 30 days alone had seen a decline of 15.81 percent. The trigger for that selloff was the company’s second-quarter earnings release on July 16, which delivered strong operational numbers but a stubbornly conservative outlook.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Revenue for the quarter reached $2.89 billion, up 19 percent year over year, while net income climbed to $818 million, or $2.29 per share — both figures ahead of analyst expectations. Global procedure volumes for the da Vinci and Ion platforms grew approximately 16 percent, and of the 468 da Vinci systems installed in the quarter, 246 were the new da Vinci 5 generation, up from 180 a year earlier. The replacement cycle is accelerating faster than many anticipated.
Yet the company declined to raise its 2026 procedure growth forecast, which remains in a range of 13.5 to 15.5 percent. Management cited the expiration of Affordable Care Act subsidies in the U.S., a regulatory change that is expected to dampen demand for elective, non-life-threatening procedures such as gallbladder and hernia repairs — precisely the types of surgeries that generate the bulk of volume on robotic platforms. While executives described the likely impact as “moderate,” the decision to hold the guidance steady signaled caution about the second half of the year.
Options Market Turns Bearish
The convergence of regulatory and earnings headwinds has left Intuitive shares trading at €298.65, just 0.20 percent above the 52-week low of €298.05 set on July 23. The 14-day relative strength index has fallen to 30.9, deep in oversold territory, reflecting the intensity of the selloff that began well before the J&J news broke.
Options activity tells a similar story. The put-call ratio for contracts expiring at the end of August stands at 1.29, a distinctly bearish signal. The lowest strike price among those contracts is $317, implying traders are positioning for a potential further decline of roughly 7 percent from current levels.
A Moat Under Pressure
Despite the mounting challenges, Intuitive retains a commanding market position. The company held a 57.6 percent share of the U.S. robotic surgery market in 2025, with Stryker and J&J’s own Auris Health trailing in second and third place. The overall market continues to expand, with projections calling for the global robotic surgery market to grow from roughly $12 billion to $20.8 billion by 2035, a compound annual growth rate of 5.6 percent.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
The near-term threat from Ottava is less about an immediate loss of market share — J&J is starting with a limited number of customers — and more about the erosion of Intuitive’s pricing power. Hospitals that have long relied almost exclusively on da Vinci systems now have a credible alternative, which could weaken Intuitive’s negotiating leverage on capital equipment and slow the growth of recurring revenue from instruments and accessories. That dynamic makes it harder to justify the premium valuation the stock has historically commanded.
A Fortress Balance Sheet
What cushions the blow is Intuitive’s financial strength. The company ended the second quarter with $8.63 billion in cash and investments, and free cash flow for the first half reached $1.8 billion, up 71 percent from the same period last year. That liquidity has funded $379 million in share buybacks during the first six months of 2026, along with continued heavy investment in research and development for endoluminal and digital platforms.
The balance sheet provides a buffer while the market digests the twin uncertainties of a new competitor and a potentially softer demand environment. How quickly J&J scales its Ottava installations will shape the competitive landscape in coming quarters, as will the actual impact of the ACA subsidy expiration on procedure volumes. For now, Intuitive’s management describes that impact as moderate — but the market is pricing in a scenario that is considerably more cautious.
Ad
Intuitive Surgical Stock: New Analysis - 23 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
